Teva Pharmaceutical Industries (TEVA) News Today

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares have increased and are trading near their 52-week high as investors respond to a significant FDA approval that strengthens the company’s branded-drug pipeline and neuroscience business.

• Positive Sentiment: The FDA approved WELTRUZA, Teva’s extended-release injectable olanzapine for adults with schizophrenia. Teva describes it as the first and only once-monthly subcutaneous olanzapine, with no loading dose, oral supplementation or post-injection monitoring required—features that could improve convenience and support commercial adoption. Reuters article on Teva Weltruza FDA approval
• Positive Sentiment: The approval was supported by the Phase 3 SOLARIS trial, which showed improvements in symptoms, illness severity, and personal and social functioning, with a safety profile consistent with oral olanzapine. This provides clinical support for the product’s launch prospects. Teva press release on WELTRUZA
• Positive Sentiment: Investors are also focused on Teva’s broader “Pivot to Growth” strategy, including its long-acting injectable neuroscience franchise and recently approved DEGEVMA biosimilar to Xgeva. DEGEVMA gives Teva a second FDA-approved biosimilar in 2026 and expands its denosumab portfolio. Seeking Alpha transcript on Teva’s strategic initiatives
• Positive Sentiment: Fresh bullish coverage, including a reported Buy rating and a $55 price target, has reinforced expectations that Teva’s branded products, generics and biosimilars can support additional growth. Quiver Quantitative analysis of Teva momentum
• Negative Sentiment: Quiver Quantitative data shows 17 insider sales and no insider purchases during the past six months. While these transactions may reflect compensation or diversification, the absence of buying is a modest negative sentiment signal. Quiver Quantitative insider trading data